Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein

PLoS Pathogens

Volumn 6, Issue 9, 2010, Pages

  Francica, Joseph R ^a   Varela Rohena, Angel ^b   Medvec, Andrew ^b   Plesa, Gabriela ^b   Riley, James L ^b   Bates, Paul ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CELL SURFACE PROTEIN; EPITOPE; GLYCAN; PROTEIN SUBUNIT; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; EBOLA VIRUS; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEPLETION; PROTEIN EXPRESSION; STEREOSPECIFICITY; VIRUS CELL INTERACTION;

ADENOCARCINOMA; ANTIGENS, CD29; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; CELLS, CULTURED; EBOLAVIRUS; EPITOPES; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HEMORRHAGIC FEVER, EBOLA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; OVARIAN NEOPLASMS; VIRAL ENVELOPE PROTEINS;

EBOLA VIRUS;

EID: 78149348506     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001098     Document Type: Article

References (52)

1. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, et al. (2001) Filoviridae: Marburg and Eboila Viruses. In: Knipe DM, Howley PM, Griggen DE, Lamb RA, Martin MA, et al., eds. Fields Virology: Lippincott, Williams & Wilkins. pp 1279-1304.
2. Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. The Lancet Infectious Diseases 4: 487-498.
3. Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 87: 1247-1257.
4. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proceedings of the National Academy of Sciences of the United States of America 93: 3602-3607.
5. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250: 408-414.
6. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95: 5762-5767.
7. Jeffers SA, Sanders DA, Sanchez A (2002) Covalent modifications of the ebola virus glycoprotein. J Virol 76: 12463-12472.
8. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886-889.
9. Chan SY, Ma MC, Goldsmith MA (2000) Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81: 2155-2159.
10. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, et al. (2000) Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278: 20-26.
11. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, et al. (2001) Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291: 1965-1969.
12. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P (2002) Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76: 2518-2528.
13. Ray RB, Basu A, Steele R, Beyene A, McHowat J, et al. (2004) Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells. Virology 321: 181-188.
14. Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, et al. (2005) Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent proteintrafficking pathway. J Virol 79: 547-553.
15. Francica JR, Matukonis MK, Bates P (2009) Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology 383: 237-247.
16. Zampieri CA, Fortin JF, Nolan GP, Nabel GJ (2007) The ERK mitogenactivated protein kinase pathway contributes to Ebola virus glycoproteininduced cytotoxicity. J Virol 81: 1230-1240.
17. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, et al. (2002) Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 195: 593-602.
18. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177-182.
19. Jentoft N (1990) Why are proteins O-glycosylated? Trends Biochem Sci 15: 291-294.
20. Wool-Lewis RJ, Bates P (1999) Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function. J Virol 73: 1419-1426.
21. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y (2002) Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 76: 406-410.
22. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. Embo J 23: 2175-2184.
23. Kuan SF, Byrd JC, Basbaum C, Kim YS (1989) Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells. J Biol Chem 264: 19271-19277.
24. Huang J, Byrd JC, Yoon WH, Kim YS (1992) Effect of benzyl-alpha-GalNAc, an inhibitor of mucin glycosylation, on cancer-associated antigens in human colon cancer cells. Oncol Res 4: 507-515.
25. Huet G, Hennebicq-Reig S, de Bolos C, Ulloa F, Lesuffleur T, et al. (1998) GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells. J Cell Biol 141: 1311-1322.
26. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
27. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, et al. (2009) Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83: 9596-9601.
28. Willey RL, Maldarelli F, Martin MA, Strebel K (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66: 7193-7200.
29. Schneider-Schaulies J, Schnorr JJ, Brinckmann U, Dunster LM, Baczko K, et al. (1995) Receptor usage and differential downregulation of CD46 by measles virus wild-type and vaccine strains. Proc Natl Acad Sci U S A 92: 3943-3947.
30. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2: 338-342.
31. Andersson M, Paabo S, Nilsson T, Peterson PA (1985) Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 43: 215-222.
32. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU (2000) Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 74: 5300-5309.
33. Wen C, He X, Ma H, Hou N, Wei C, et al. (2008) Hepatitis C virus infection downregulates the ligands of the activating receptor NKG2D. Cell Mol Immunol 5: 475-478.
34. Thomas M, Boname JM, Field S, Nejentsev S, Salio M, et al. (2008) Downregulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A 105: 1656-1661.
35. Hewitt EW (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110: 163-169.
36. Beck M, Strand MR (2005) Glc1.8 from Microplitis demolitor bracovirus induces a loss of adhesion and phagocytosis in insect high five and S2 cells. J Virol 79: 1861-1870.
37. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265.
38. Komatsu M, Yee L, Carraway KL (1999) Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokineactivated killer cells. Cancer Res 59: 2229-2236.
39. Pino V, Ramsauer VP, Salas P, Carothers Carraway CA, Carraway KL (2006) Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition. J Biol Chem 281: 29411-29420.
40. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60.
41. Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of Ecadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7: 565-577.
42. Fukuda M (2002) Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys Acta 1573: 394-405.
43. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
44. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3: e9.
45. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73: 6024-6030.
46. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG (1995) Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26: 432-439.
47. Sherblom AP, Moody CE (1986) Cell surface sialomucin and resistance to natural cell-mediated cytotoxicity of rat mammary tumor ascites cells. Cancer Res 46: 4543-4546.
48. Bertozzi CC, Chang CY, Jairaj S, Shan X, Huang J, et al. (2006) Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell Dev Biol Anim 42: 58-62.
49. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, et al. (2007) Engineering artificial antigen-presenting cells to express a diverse array of costimulatory molecules. Mol Ther 15: 981-988.
50. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL (2003) CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 171: 166-174.
51. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, et al. (2008) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14: 1390-1395.
52. Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, et al. (2003) Differential Nlinked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 77: 1337-1346.